Compounded Semaglutide: What It Is and Whether It's Safe

If you have shopped online for a weight loss shot in the last two years, you have seen the pitch: the same active ingredient as Ozempic and Wegovy, for a fraction of the price, shipped to your door. That product is compounded semaglutide, and it is a genuinely different thing from the drug in a Novo Nordisk pen.

This guide explains what compounding is, what the safety record actually shows, and what questions to bring to a healthcare provider. It is not medical advice, and it does not tell you what to take.

What is compounded semaglutide?

Compounding is the practice of a licensed pharmacy mixing or altering ingredients to make a medication for a patient. It is a legitimate, long-standing part of pharmacy. A child who cannot swallow a tablet may need a liquid version. Someone allergic to a dye in a commercial product may need it made without that dye.

Compounded semaglutide is semaglutide powder, usually purchased as a bulk active pharmaceutical ingredient, that a pharmacy dissolves and puts into a vial. The patient draws each dose out of the vial with a syringe rather than dialing it on a pen.

The single most important fact about it is this: compounded drugs are not FDA approved. The FDA states plainly that it does not review compounded drugs for safety, effectiveness, or quality before they are marketed [1][2]. There is no application, no manufacturing approval, no review of the clinical data, because there is no clinical data on that specific product.

That is not a technicality. When you take Wegovy, you are taking something that went through trials in thousands of people and is made in a plant FDA inspects against a specific approved process. When you take compounded semaglutide, you are taking something a pharmacy assembled, and the only evidence behind it is the evidence for the branded drug it resembles.

Is compounded semaglutide the same as Ozempic or Wegovy?

Companies have repeatedly said yes. The FDA has repeatedly said that claim is false or misleading.

In September 2025 FDA sent a warning letter to Hims & Hers over website language describing its product as a “weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy” and as using “clinically proven ingredients” [3]. On February 20, 2026 it sent a similar letter to the telehealth company MEDVi over “Same active ingredient as Wegovy and Ozempic” claims; MEDVi has publicly disputed receiving it, saying the cited website belonged to an affiliate. FDA’s public guidance to telehealth companies now lists the specific moves it considers deceptive: calling a compounded drug generic, calling it equivalent, implying FDA approval, claiming identical clinical results, or describing a pharmacy as FDA-approved or FDA-licensed [2].

There are three concrete ways a compounded product can differ from the approved one.

The active ingredient may be a different chemical form. FDA has warned that some compounded and imported products contain semaglutide sodium or semaglutide acetate rather than the semaglutide base used in Ozempic, Wegovy, and Rybelsus. The agency says these are different active ingredients and that it does not have information on whether they share the same chemical and pharmacologic properties [1].

The formulation may include extra ingredients. Many compounded products add cyanocobalamin (vitamin B12), glycine, or niacinamide. There is no evidence that adding B12 improves weight loss. The additions exist largely for formulation and legal reasons, and FDA has said a semaglutide plus B12 injection can still count as essentially a copy of the commercial product.

The strength may not match any approved dose. Compounded products are often sold at doses that do not exist in an approved pen, including very low “microdoses.”

What does the safety record actually show?

Four distinct problems show up in the public record.

1. Dosing errors

This is the best-documented risk, and it is the one most specific to compounding. Approved semaglutide comes in a pen that delivers a fixed dose when you dial it. Compounded semaglutide usually comes in a multi-dose vial, and you draw the dose yourself with a syringe.

FDA has alerted providers, compounders, and patients to overdoses caused by patients measuring the wrong volume and by clinicians miscalculating doses [4]. A peer-reviewed case series in the Journal of the American Pharmacists Association documented patients who administered ten times the intended dose, with nausea, vomiting, and abdominal pain that lasted for days [5].

The underlying trap is units. A prescription may be written in milligrams, the vial labeled in milligrams per milliliter, and the syringe marked in insulin “units.” Confusing those scales is how a 0.25 mg dose becomes a 2.5 mg dose.

2. Sterility and manufacturing problems

Injectable drugs have to be sterile. Compounding pharmacies have repeatedly failed that test.

In April 2025 FDA issued two warning letters on the same day to Empower Pharmacy in Houston, one to its 503A pharmacy and one to its 503B outsourcing facility, citing insanitary conditions in sterile drug production and deficient corrective actions [6]. Empower was one of the largest suppliers of compounded GLP-1s to telehealth platforms.

Recalls followed a similar pattern. ProRx semaglutide injections were the subject of a Class II recall classified by FDA in October 2025 for lack of sterility assurance [7]. In July 2026 the 503B outsourcing facility Apollo Care recalled roughly 156,611 vials of compounded semaglutide and about 5,500 vials of semaglutide with glycine after nylon, polyamide, and proteinaceous particulate matter was found in vials [8].

If you are taking a compounded product, it is worth knowing which pharmacy makes it, because that is the only way to check whether it has been the subject of a recall. FDA maintains a public page listing compounding inspections, recalls, and other actions [9].

3. Adverse event reports

Through May 31, 2026, FDA had logged more than 1,700 adverse event reports naming compounded GLP-1s: roughly 990 for compounded semaglutide and more than 730 for compounded tirzepatide [10]. Those are reports, not proven cause-and-effect findings.

The more important caveat runs the other way. FDA notes the totals are likely undercounts, because state-licensed 503A pharmacies are not required to report adverse events the way manufacturers are. With an approved drug, there is a legal reporting chain. With a compounded drug from a 503A pharmacy, there often is not.

4. You often cannot verify what is in the vial

With an approved product, the label tells you the manufacturer, the lot, and the expiration date, and the supply chain is tracked under federal law. With a compounded product, the vial may carry the telehealth brand’s name rather than the pharmacy’s. FDA specifically cited that practice as misleading in its MEDVi warning letter, because it suggested the telehealth company was the compounder when it was not.

What about “research peptides” sold without a prescription?

This is a separate and riskier market, and it should not be confused with pharmacy compounding.

Research-peptide vendors sell semaglutide, tirzepatide, retatrutide, and other compounds as powder labeled “for research purposes only” or “not for human consumption.” There is no prescription, no pharmacist, and no clinician. The seller supplies its own certificate of analysis.

FDA does not accept the labeling as a defense. In March 2026 it issued warning letters to Gram Peptides and Prime Sciences, concluding that the products were intended as human drugs because of how they were marketed and described [11]. A further batch dated August 24, 2026 went to sellers listing retatrutide, semaglutide, tirzepatide, elamipretide, and tesamorelin alongside bacteriostatic water for reconstitution. FDA has also said that retatrutide and cagrilintide cannot lawfully be used in compounding at all, and that neither has been found safe and effective for any indication.

There is now direct evidence about how this goes wrong in practice. A 2026 study asked adults to prepare and use gray-market peptide semaglutide acquired without a prescription. Participants completed only 15 of 34 steps correctly, with errors that could cause incorrect dosing, needle sticks, or infection [12].

What about microdosing?

Microdosing means taking less than the lowest approved starting dose, usually on the theory that it produces fewer side effects.

The honest answer is that nobody knows whether it works or whether it is safe over time. There are no large trials of sub-approved doses, no standardized protocols, no agreed dosing ranges, and no long-term safety data [13][14]. Because approved pens do not deliver those amounts, microdosing in practice almost always means buying a compounded product, which brings back every issue above.

What do professional groups say?

The American Diabetes Association has advised against using non-FDA-approved compounded incretin products such as compounded semaglutide and tirzepatide, recommending a switch to a different approved medication during shortages, citing lack of FDA review, dosing errors, and counterfeiting risk [15]. The Obesity Society publicly supported FDA action against unapproved and misleading compounded GLP-1 marketing in February 2026.

That does not mean every person using a compounded product has been harmed. Many have not. It means the professional consensus is that the risk is avoidable when an approved product is available.

Questions worth asking before you start or continue

If you are weighing a compounded product, these are the things a prescriber and a pharmacy should be able to answer.

• Is this product FDA approved? (If the answer is anything other than a clear no, that is itself a red flag.)
• Which pharmacy compounds it, and is it a 503A pharmacy or a 503B outsourcing facility?
• Is that pharmacy currently licensed in its state, and has it had recalls or FDA warning letters?
• What exact form of semaglutide is used, and does the product contain anything besides semaglutide?
• Will I be drawing doses from a vial, and who will show me how to measure correctly?
• What is the beyond-use date, and how should it be stored when it arrives?
• If I have a side effect, who reports it, and to whom?

The bottom line

Compounded semaglutide filled a real gap during a real shortage. That shortage ended in February 2025, and the legal and commercial logic behind the mass-market version collapsed with it.

What remains is a product that has never been reviewed by FDA, that has a documented history of dosing errors and sterility recalls, that is often marketed with claims FDA has formally called false, and that is now frequently more expensive than the approved alternative once you add the membership fee. The price argument that made it compelling in 2024 is much weaker in 2026, with branded self-pay prices at $349 a month for Wegovy pens and as low as $149 for starter doses of the Wegovy pill (verified 2026-09-14 on novocare.com). Both are self-pay prices through Novo’s own pharmacy, not list prices and not insurance copays, and Novo’s page states they are due to be updated after December 31, 2026.

If you are currently using a compounded product, changes to what you take are a conversation for a healthcare provider rather than something to work out from an article. That conversation is also the place to find out what approved options you qualify for and what your insurance, the Medicare GLP-1 Bridge Program, or a manufacturer direct-pay program would actually cost.

Sources

1. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA
2. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs — FDA
3. Warning Letter: Hims & Hers Health, Inc. dba Hers, September 9, 2025 — FDA
4. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products — FDA
5. Administration errors of compounded semaglutide reported to a poison control center — Journal of the American Pharmacists Association
6. Warning Letter: Empower Clinic Services, LLC dba Empower Pharmacy, April 2, 2025 — FDA
7. Class II Recall for ProRx Semaglutide Injections Due to Lack of Sterility Assurance — Pharmacy Learning Network
8. FDA Recalls and Warnings: Foreign Particles Found in Compounded Semaglutide — MedShadow Foundation
9. Compounding: Inspections, Recalls, and other Actions — FDA
10. FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide — Drug Discovery & Development
11. Warning Letter: Gram Peptides, March 31, 2026 — FDA
12. Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription — PubMed
13. Microdosing GLP-1s: Does It Work? Risks and Benefits — GoodRx
14. Should You Microdose GLP-1 Medications? — Cleveland Clinic
15. Direct-to-Consumer Telehealth Companies: What Clinicians Should Know — Rheumatology Advisor